JAN 22, 2020 12:21 PM PST

How the VISTA molecule affects immune responses

A new study describes how a molecule named VISTA has been impeding immune responses in cancer therapies. By turning this molecule “off,” researchers from Dartmouth Hitchcock's Norris Cotton Cancer Center have figured out how to improve immune responses in patients receiving anticancer treatments. The study was published under the title, "VISTA, a checkpoint regulator of naïve T-cell quiescence and tolerance in the periphery” in the journal Science.

"We have learned that keeping your immune system quiet is a challenging and very active process," says lead investigator Randolph Noelle, PhD. "VISTA mediates immune system function and its loss can result in the development of unwanted immune responses. But VISTA may also be a valuable target in regulating the immune response in cancer and autoimmunity."

VISTA is what scientists call a negative checkpoint regulator. That means that it tempers the immune system in order to stop the activation of self-antigens like cancer cells. "Like other negative checkpoint regulators, blocking VISTA in cancer may enhance the host's ability to make protective tumor-specific immune responses," says Noelle.

Noelle and the team of researchers have been working on understanding the role of the VISTA molecule, which stands for V-domain Ig suppressor of T-cell activation, for almost ten years. Finally, as the authors write in the study, they have something to show for all their hard work:

“Therapeutic targeting of VISTA using an agonistic antibody in mice curbed the development of graft-versus-host disease and promoted the death of naïve T cells abnormally activated by self-antigen. VISTA thus represents a distinctive immunoregulatory molecule that controls naïve T cell function by maintaining quiescence and peripheral tolerance.”

New research aims to understand VISTA's role in the immune system. Photo: Pixabay

The researchers hope to use this finding to run clinical trials to determine if their research can be used outside of mice in human patients with cancer. As Science Daily reports, if this is possible, “this antibody may be valuable in the development of drugs and vaccines to provide therapeutic response to cancer and cancer cures.”

Sources: Science, Science Daily

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
NOV 29, 2019
Immunology
NOV 29, 2019
Protecting Killer Immune Cells from Themselves
Destroying human cells compromised by viruses and cancer is the name of the game for so-called “killer” cells of the immune system. They employ...
DEC 09, 2019
Cancer
DEC 09, 2019
Hair dyes associated with increased risk of breast cancer
Research recently published in the International Journal of Cancer suggests that certain hair dyes and chemical relaxants are associated with breast cancer...
DEC 18, 2019
Cancer
DEC 18, 2019
Looking to this tropical plant for future pancreatic cancer treatments
Pancreatic cancer is a dangerous disease for two reasons: its stealth and its resistance to many anti-cancer drugs. The American Cancer Society estimates t...
JAN 08, 2020
Health & Medicine
JAN 08, 2020
Cancer Death Rates Declining in U.S., According to New Report
In the United States, the death rate from cancer has declined, according to a new report released today by the American Cancer Society. The video below sum...
JAN 14, 2020
Cancer
JAN 14, 2020
Could the flu vaccine shrink cancer tumors?
If you’ve been to the doctor recently, you’ve probably been asked if you want a flu shot this year. The flu vaccine is popular because it reduc...
JAN 21, 2020
Cancer
JAN 21, 2020
A gene for leukemia triggers the growth of stem blood cells
New research from the University of Colorado Cancer Center has identified a way to make hematopoietic stem cells from a gene that causes a type of leukemia...
Loading Comments...